gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Immunoglobulin superfamily, member 9

Top mentioned proteins: HAD, CD4, CAN, AGE, iMpact
Papers on NRTI
Backbones versus core agents in initial ART regimens: one game, two players.
Gatell et al., Toronto, Canada. In J Antimicrob Chemother, Feb 2016
It appears that at least one NRTI is needed for optimal performance and lamivudine and emtricitabine may be the ideal candidates.
Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Viale et al., Bologna, Italy. In Hiv Clin Trials, Feb 2016
BACKGROUND: Nucleoside reverse transcriptase inhibitor (NRTI)-sparing antiretroviral therapies may be useful in HIV-infected patients with resistance or intolerance to this class.
HIV drug resistance among children initiating first-line Antiretroviral Treatment (ART) in Uganda.
Mugyenyi et al., Kampala, Uganda. In Aids Res Hum Retroviruses, Feb 2016
Nucleoside reverse transcriptase inhibitors (NRTI), non-NRTI (NNRTI) and dual-class resistance was present in 5.7%, 7.5% and 3.2% respectively.
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.
Lataillade et al., Indianapolis, United States. In Lancet Hiv, Jan 2016
BACKGROUND: BMS-986001 is a thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) designed to maintain in-vitro antiviral activity while minimising off-target effects.
The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/Emtricitabine-containing HAART Regimens.
Chang et al., Taegu, South Korea. In Infect Chemother, Dec 2015
BACKGROUND: The combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) has been the first choice nucleoside reverse transcriptase inhibitor (NRTI) according to many reliable antiretroviral treatment (ART) guidelines because of its high efficacy.
Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching.
Lee et al., Taegu, South Korea. In Infect Chemother, Dec 2015
The group receiving PI-and NRTI-based regimens were most likely to switch due to adverse effects during the early treatment period.
Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development.
Hu et al., United States. In Antiviral Res, Nov 2015
Thus, a nucleoside RT inhibitor (NRTI) can functionally mimic a non-NRTI (NNRTI) in its inhibition of the HBV RT.
Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Deeks et al., Auckland, New Zealand. In Drugs, Apr 2015
In the SINGLE trial, there were no major treatment-emergent INSTI or NRTI resistance-associated mutations in dolutegravir plus abacavir/lamivudine recipients with protocol-defined virological failure, indicating a high genetic barrier to resistance.
Fetal consequences of maternal antiretroviral nucleoside reverse transcriptase inhibitor use in human and nonhuman primate pregnancy.
Blanche et al., Paris, France. In Curr Opin Pediatr, Apr 2015
RECENT FINDINGS: In the offspring of pregnant patas monkeys given human-equivalent NRTI protocols, aneuploidy was found in cultured bone marrow cells taken at birth, 1, and 3 years of age.
[Lopinavir/ritonavir in new initial antiretroviral treatment strategies].
Cahn et al., Buenos Aires, Argentina. In Enferm Infecc Microbiol Clin, 2014
According to evidence from randomized controlled trials and epidemiological data, the antiretroviral treatment (ART) of choice has consisted of the combination of 2 nucleoside analog reverse-transcriptase inhibitors (NRTI) plus 1 non-nucleoside analog reverse-transcriptase inhibitor (NNRTI) or a protease inhibitor (PI) for more than 17 years.
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.
International Antiviral Society-USA Panel et al., Zürich, Switzerland. In Jama, 2014
Boosted protease inhibitor monotherapy is generally not recommended, but NRTI-sparing approaches may be considered.
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
EARNEST Trial Team et al., Singapore, Singapore. In N Engl J Med, 2014
METHODS: In this open-label trial in sub-Saharan Africa, we randomly assigned 1277 adults and adolescents with HIV infection and first-line treatment failure to receive a ritonavir-boosted protease inhibitor (lopinavir-ritonavir) plus clinician-selected NRTIs (NRTI group, 426 patients), a protease inhibitor plus raltegravir in a superiority comparison (raltegravir group, 433 patients), or protease-inhibitor monotherapy after 12 weeks of induction therapy with raltegravir in a noninferiority comparison (monotherapy group, 418 patients).
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
ING114915 Study Team et al., Vic, Spain. In Lancet, 2014
Randomisation was stratified by screening HIV-1 RNA (≤100,000 or >100,000 copies per mL) and nucleoside reverse transcriptase inhibitor (NRTI) selection.
Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.
Gibb et al., In Lancet, 2013
INTERPRETATION: NNRTI plus NRTI-based three-drug or four-drug ART can be given across childhood without routine toxicity monitoring; CD4 monitoring provided clinical benefit after the first year on ART, but event rates were very low and long-term survival high, suggesting ART rollout should take priority.
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
Essex et al., Boston, United States. In N Engl J Med, 2010
RESULTS: The rate of virologic suppression to less than 400 copies per milliliter was high and did not differ significantly among the three groups at delivery (96% in the NRTI group, 93% in the protease-inhibitor group, and 94% in the observational group) or throughout the breast-feeding period (92% in the NRTI group, 93% in the protease-inhibitor group, and 95% in the observational group).
The protein dendrite arborization and synapse maturation 1 (Dasm-1) is dispensable for dendrite arborization.
Klein et al., Martinsried, Germany. In Mol Cell Biol, 2008
dendrite arborization phenotype was caused by off-target effects and that Dasm-1 is dispensable for hippocampal dendrite arborization
Dasm1: a receptor that shapes neuronal dendrites and turns on silent synapses?
Falls, Atlanta, United States. In Sci Stke, 2005
Review. Dasm1, a protein likely to function as a neuronal cell-surface receptor, plays an important role in both shaping the dendritic tree and affecting the fraction of electrically active glutamatergic synapses.
share on facebooktweetadd +1mail to friends